SynthesisFrontiers in psychiatry2026
Clinical practice guidelines and quality standards for early intervention in psychosis: an AGREE II appraisal and systematic review of service components.
Synthesis in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effectiveness and safety of long-acting aripiprazole 960 mg: preliminary findings from a prospective real-world observational study.International clinical psychopharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early intervention in psychosis (EIP) is a key component of youth mental health care, yet recommended models of care for individuals at clinical high risk for psychosis (CHR-P) and first-episode psychosis (FEP) remain heterogeneous across jurisdictions. No previous study has combined a formal AGREE II appraisal with a structured synthesis of core service components for EIP. Methods: We conducted a systematic review and AGREE II-based appraisal of international clinical practice guidelines (CPGs) and quality standards (QSs). MEDLINE (via PubMed), the Cochrane Library (CENTRAL), Web of Science, guideline repositories, and grey literature sources were searched to March 2025 in accordance with PRISMA 2020 guidance. Eligible documents were CPGs or QSs published in English or Italian from 2005 onward containing recommendations on the organization, assessment, and treatment of CHR-P and/or FEP. Methodological quality was appraised with AGREE II (inter-rater agreement assessed using ICCs); recommendations were extracted, and core components required endorsement by at least one third of relevant documents with at least one strong or mandatory recommendation. Twenty-six documents (24 CPGs and 2 QSs) were included. Methodological quality was moderate overall, with substantial variability across AGREE II domains: scores were generally strongest for scope and purpose, stakeholder involvement, and clarity of presentation, and more variable for Rigour of development, applicability, and editorial independence. Results: We identified 32 core recommendations. For CHR-P, the most consistent components were specialized services or dedicated pathways, comprehensive multidisciplinary assessment, cognitive-behavioural therapy, family interventions, and a cautious approach to antipsychotic use. For FEP, the most consistently endorsed components were specialized multidisciplinary teams, assertive and continuous follow-up, family work, psychoeducation, structured pharmacological monitoring, and supported education and employment. Conclusion: These findings provide a guideline-derived framework for youth EIP service delivery and model development, while highlighting the need for more methodologically robust and implementation-oriented guidance across settings. Systematic review registration: https://osf.io/cek7u, identifier cek7u.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.